See more : Banpu Public Company Limited (BNPJY) Income Statement Analysis – Financial Results
Complete financial analysis of Bionoid Pharma Inc. (BINP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bionoid Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Guangdong AVCiT Technology Holding Co., Ltd. (001229.SZ) Income Statement Analysis – Financial Results
- GoPro, Inc. (5G5.DE) Income Statement Analysis – Financial Results
- Samhällsbyggnadsbolaget i Norden AB (publ) (SBB-B.ST) Income Statement Analysis – Financial Results
- Oriental Explorer Holdings Limited (0430.HK) Income Statement Analysis – Financial Results
- Wood Friends Co.,Ltd. (8886.T) Income Statement Analysis – Financial Results
Bionoid Pharma Inc. (BINP)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://bionoidpharma.com
About Bionoid Pharma Inc.
Bionoid Pharma Inc. engages in the hemp cultivation business. The company is based in Beverly Hills, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.51K | 36.04K | 102.12K | 30.66K | 56.17K | 92.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 29.09K | 18.69K | 56.11K | 16.59K | 0.00 | 44.77 | 7.64K | 252.46K | 181.50K | 43.83K | 0.00 | 0.00 |
| Gross Profit | 8.42K | 17.35K | 46.01K | 14.07K | 56.17K | 47.48 | -7.64K | -252.46K | -181.50K | -43.83K | 0.00 | 0.00 |
| Gross Profit Ratio | 22.44% | 48.13% | 45.05% | 45.90% | 100.00% | 51.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 602.84K | 483.59K | 134.50K | 134.33K | 151.22K | 212.06K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 365.70 | 0.00 | 3.15M | 2.79M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.55 | 0.00 | 0.00 | -181.50K | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74K | 15.49K | 125.84K | 3.25K | 16.70K | 436.25 | 4.21M | 3.15M | 2.61M | 1.08M | 772.40K | 1.62M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -43.30K | 0.00 | 0.00 | -314.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.74K | 15.49K | 125.84K | 46.55K | 16.70K | 1.60K | 5.13M | 3.63M | 2.75M | 1.22M | 923.62K | 1.83M |
| Cost & Expenses | 44.83K | 34.18K | 181.95K | 63.14K | 19.70K | 1.64K | 5.14M | 3.88M | 2.93M | 1.22M | 923.62K | 1.83M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 69.00 | 0.00 | 0.00 | 43.00 | 0.00 | 15.00 | 20.00 |
| Interest Expense | 481.00 | 380.00 | 393.00 | 0.00 | 202.00 | 0.00 | 2.89K | 22.10K | 484.26K | 369.78K | 338.29K | 246.45K |
| Depreciation & Amortization | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 3.31 | 7.64K | 33.89K | 39.79K | 43.83K | 334.20K | 277.29K |
| EBITDA | -4.32K | 4.86K | -131.87K | -29.48K | 30.35K | -385.71 | -5.13M | -3.85M | -2.89M | -1.18M | -589.42K | -1.55M |
| EBITDA Ratio | -11.53% | 13.48% | -75.24% | -96.16% | 70.28% | -418.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.32K | 1.86K | -79.83K | -32.48K | 36.48K | -389.02 | -5.14M | -3.88M | -2.93M | -1.22M | -923.62K | -1.83M |
| Operating Income Ratio | -19.53% | 5.16% | -78.17% | -105.95% | 64.94% | -421.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -481.00 | -382.00 | -55.43K | -423.30K | -9.33K | -1.23K | -2.89K | -22.10K | -484.21K | -369.78K | -338.28K | -246.43K |
| Income Before Tax | -7.81K | 1.48K | -135.26K | -455.78K | 27.15K | -1.62K | -5.14M | -3.91M | -3.41M | -1.59M | -1.26M | -2.08M |
| Income Before Tax Ratio | -20.81% | 4.10% | -132.45% | -1,486.72% | 48.33% | -1,757.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -7.81K | 2.00 | -1.00 | 0.00 | 0.00 | 1.97 | 2.35K | 1.72K | 959.00 | 863.00 | 1.59K | 577.00 |
| Net Income | -7.81K | 1.48K | -135.26K | -455.78K | 27.15K | -1.62K | -5.14M | -3.91M | -3.41M | -1.59M | -1.26M | -2.08M |
| Net Income Ratio | -20.81% | 4.10% | -132.45% | -1,486.72% | 48.33% | -1,759.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | -11.88 | 0.70 | -46.37 | -335.25 | -0.13 | -0.16 | -0.09 | -0.08 | -0.13 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -11.88 | 0.70 | -46.27 | -335.25 | -0.13 | -0.16 | -0.09 | -0.08 | -0.13 |
| Weighted Avg Shares Out | 53.99M | 53.99M | 42.67M | 38.36K | 38.22K | 35.00 | 15.34K | 29.74M | 21.69M | 16.83M | 16.00M | 15.43M |
| Weighted Avg Shares Out (Dil) | 53.99M | 53.99M | 42.67M | 38.36K | 38.22K | 35.07 | 15.34K | 29.74M | 21.69M | 16.83M | 16.00M | 15.43M |
AI Maverick: The Next Evolution of Sales Automation Unveiled in Exclusive Podcast
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Bionoid Pharma (OTC PINK:BINP) unveils AI Maverick's game-changing sales automation in the latest episode of the BizUnLearned Podcast. Discover how this revolutionary platform is set to transform the traditional sales...
The End of SDRs? AI Maverick Sales Automation, One Touchpoint at a Time
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) - Bionoid Pharma, Inc. ("Bionoid") ("BINP") (OTC Pink:BINP), the new owner of the AI Maverick platform, is disrupting the world of sales and...
Bionoid Pharma, Inc. Launches Enhanced Supplements Ltd. to Drive Strategic E-Commerce Expansion
TORONTO, ON / ACCESSWIRE / November 19, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is excited to announce the incorporation of its wholly owned subsidiary, Enhanced Supplements Ltd., a critical step in advancing the company's strategic transition to a...
Bionoid Pharma, Inc. Signs Binding Letter of Intent to Acquire Main E-Commerce Platform of Your Supplement Supply Store Ltd.
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is excited to announce the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd. to acquire its leading e-commerce platform,...
Bionoid Pharma, Inc. Engages Olayinka Oyebola & Co. as PCAOB External Auditor for Annual Financial Audit
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is pleased to announce the formal engagement of Olayinka Oyebola & Co., a PCAOB-registered firm, as the company's external auditor. This...
Bionoid Pharma, Inc. Unveils Five-Year Strategic Roadmap
AI-Driven Platform and Strategic Acquisitions to Drive Health & Wellness Growth and Profitability TORONTO, ON / ACCESSWIRE / November 5, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) has outlined a five-year roadmap focused on expanding revenue streams and brand...
Bionoid Pharma Inc. Provides Update on Binding Letter of Intent to Acquire Global Alerts Corp.
" Paving the Way for a Safer World Through Advanced Emergency Communications " TORONTO, ON / ACCESSWIRE / December 8, 2023 / Bionoid Pharma, Inc. ("BINP" or the "Company") (OTC PINK:BINP) is pleased to announce a significant development in its...
Bionoid Pharma Signs Exclusive License Agreement with Global Alerts Corp.
Landmark Deal Signed in Global Mass Notification Market: Exclusive License Agreement for Rapid Deployment of World-Leading Early Warning Technology TORONTO, ON / ACCESSWIRE / October 12, 2023 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce an exclusive...
Bionoid Pharma Extends Letter of Intent to Acquire Global Alerts Corp.
" Paving the Way for a Safer World Through Advanced Emergency Communications " TORONTO, ON / ACCESSWIRE / August 24, 2023 / Bionoid Pharma, Inc. ("BINP" or the "Company") (OTC PINK:BINP) is pleased to announce the extension of the effective...
Source: https://incomestatements.info
Category: Stock Reports